Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815376 | 0.89 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBKDM4EKMT2AMEN1 | |
| SCHEMBL2812983 | 0.84 | FBP1 (0.47) | SMN1; SMN2FBP1KMT2AALDH1A1 | |
| SCHEMBL2814384 | 0.82 | FBP1 (0.46) | SMN1; SMN2FBP1KMT2AMEN1RAB9A | |
| SCHEMBL2816377 | 0.82 | FBP1 (0.45) | POLBFBP1KMT2AMEN1RAB9A | |
| SCHEMBL2814552 | 0.82 | FBP1 (0.46) | FBP1KMT2ARAB9AALDH1A1 | |
| SCHEMBL2816853 | 0.81 | FBP1 (0.43) | SMN1; SMN2POLBFBP1KMT2AMEN1 | |
| SCHEMBL2817159 | 0.81 | FBP1 (0.48) | SMN1; SMN2POLBFBP1KMT2AMEN1 | |
| SCHEMBL3992247 | 0.80 | FBP1 (0.45) | FBP1 | |
| SCHEMBL2815726 | 0.80 | FBP1 (0.46) | SMN1; SMN2FBP1KMT2AMEN1RAB9A | |
| SCHEMBL2816512 | 0.80 | FBP1 (0.46) | SMN1; SMN2POLBKDM4EFBP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | SDHA, SDHB, TPD52L2 | SMN1; SMN2 3994/4885POLB 2686/4885KDM4E 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.